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Aims: To identify factors associated with achievement of glycated haemoglobin A1c (HbA1c)
target at 24 weeks after commencing basal insulin therapy in individuals with type 2 diabetes
mellitus (T2DM).
Materials and methods: Post-hoc pooled analysis of 16 randomized, treat-to-target trials involv-
ing individuals with T2DM inadequately controlled with oral anti-hyperglycaemic drugs
(n = 3415) initiated on once-daily insulin glargine 100 U/mL (Gla-100). Clinical outcomes were
assessed by HbA1c response at 24 weeks and individuals were classified as “good responders”
with HbA1c <7.0% (<53 mmol/mol) or as “poor responders” with HbA1c ≥7.0% (≥53 mmol/
mol). Univariable and multivariable stepwise logistic regression analyses were performed to
identify predictive factors for attaining HbA1c <7.0%.
Results: Lower levels of baseline HbA1c, fasting plasma glucose (FPG) and post-prandial plasma
glucose (PPG), higher body mass index (BMI), shorter diabetes duration and male sex were asso-
ciated with a good glycaemic response, but not age or baseline C-peptide levels. Gla-100 dose
(U/kg) was highest in the poor-responder group, which had the fewest hypoglycaemia episodes.
Univariable analysis for achievement of HbA1c <7.0% confirmed these observations. Multivari-
able analysis retained baseline HbA1c, body weight, BMI, sex, 2-hours PPG and diabetes dura-
tion as predictors of a good response. Continued use of sulfonylureas, hypoglycaemia and
change in body weight were indicative of poor response.
Conclusions: Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0%
by supplementary Gla-100 therapy, while sex and BMI were also useful indicators. However,
age and C-peptide levels at baseline did not predict glycaemic response to the introduction of
basal insulin.
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1 | INTRODUCTION
Current treatment guidelines recommend a glycated haemoglobin A1c
(HbA1c) level of less than 7.0% (<53 mmol/mol) as the goal for most
individuals with type 2 diabetes mellitus (T2DM).1,2 The American Dia-
betes Association (ADA)2 guidelines recommend a stepwise approach
to therapies if glycaemic targets are not achieved, with basal insulin
considered as second-line or later therapy, with the exception of very
poor glycaemic control (HbA1c >9.0%; >75 mmol/mol). Similarly, the
recently updated ADA/European Association for the Study of Diabetes
(EASD) consensus report recommends a stepwise approach to thera-
pies in individuals with T2DM who are not at glycaemic target. How-
ever, with the exception of patients with HbA1c >11.0% (97 mmol/
mol), addition of a glucagon-like peptide-1 receptor agonist (GLP-1 RA)
as first injectable is recommended, with addition of basal insulin as
second injectable.3
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Currently, 24%-54% of individuals with T2DM worldwide pre-
scribed supplementary basal insulin do not achieve their therapeutic
targets.4 Clinical inertia, defined as failure to adequately intensify
treatment regimens sufficiently early, is an important contributing fac-
tor.5 Identifying biomedical predictors of treatment success may assist
clinicians in the selection of therapeutic interventions. Therefore, a
better understanding of the relationship between baseline characteris-
tics and glycaemic outcomes may help to prevent unnecessary delay
in optimizing the use of basal insulin therapy. Previous studies have
investigated the relevance of baseline characteristics to determine
effective outcomes in individuals with T2DM who are initiating insulin
therapy.4,6–9 Those characteristics that have been shown to be associ-
ated with an inadequate glycaemic response, that is, not achieving
HbA1c less than 7.0% (<53 mmol/mol), include the number of oral
anti-hyperglycaemic drugs (OADs) prescribed at baseline, in addition
to HbA1c, fasting plasma glucose (FPG) levels, body mass index (BMI),
diabetes duration and sex.4,6–9
The goal of this pooled participant-level analysis of 16 randomized
controlled clinical trials (RCTs) was to further investigate, in a larger
cohort exposed to the same basal insulin treatment, which baseline and
post-baseline characteristics better predict the glycaemic response and
achievement of HbA1c less than 7.0% at 24 weeks with the introduc-
tion and titration of basal insulin glargine 100 units (U)/mL (Gla-100),
administered once daily at bedtime in combination with existing OADs.
2 | MATERIALS AND METHODS
2.1 | Study and participant selection
Participant-level data were collected and pooled for analysis from
RCTs of up to 24 weeks, conducted by Sanofi, the manufacturer of
Gla-100 (Lantus, Paris, France) between 2000 and 2015. To fulfil the
inclusion criteria for this analysis, all trials were required to enrol
insulin-naïve individuals whose T2DM was inadequately controlled
(HbA1c >7.0%; >53 mmol/mol) while using OADs, with at least one
study arm commencing once-daily Gla-100, and no other basal insulin,
and using a titration algorithm, predominantly a once-weekly dose
adjustment of 2-8 U/d, based on the patient's self-measured plasma
glucose (SMPG) to achieve an FPG of ≤5.6 mmol/L (≤100 mg/dL). Six-
teen studies that met the inclusion criteria were identified and have
been described elsewhere.9 All study participants (N = 3415) for
whom data were analysed were mainly receiving one (metformin or
sulfonylurea) or two OADs (metformin with a sulfonylurea); a few par-
ticipants received other OADs alone or in combination (eg, gliptin,
thiazolidinedione or glinide) with Gla-100 (Figure S1).
2.2 | Outcomes
All clinical outcomes were assessed over the 24-week study period
according to response, with participants stratified by HbA1c level at
24 weeks into “good responders” reaching HbA1c less than 7.0%
(<53 mmol/mol) and “poor responders” with HbA1c ≥7.0%
(≥53 mmol/mol). Outcomes in the poor responder group were further
divided into “suboptimal” (7.0%-8.0%; 53-64 mmol/mol) and “minimal”
(>8.0%; >64 mmol/mol) responder subgroups. Hypoglycaemia was
defined as a confirmed plasma glucose (PG) level of <3.9 mmol/L
(<70 mg/dL) or as severe hypoglycaemia requiring third-party assistance.
Baseline characteristics and treatment-emergent events within the two
responder groups were analysed primarily to identify factors that pre-
dicted achievement of an HbA1c target of <7.0% (<53 mmol/mol) at
24 weeks. Glycaemic outcomes per responder group were also sub-
analysed according to the frequency of hypoglycaemia events (ie, 0, 1-3,
and ≥ 4 events) during the 24-week study. Average 2-hour post-prandial
SMPG (2-h SMPG) was derived from the mean of the 2-hour post-break-
fast, lunch and evening meal, both before baseline and at the Week
24 visit.
2.3 | Statistical analysis
Baseline parameters and clinical outcomes were presented descriptively
up to 24 weeks. Univariable and multivariable analyses included all partic-
ipants with a baseline HbA1c of ≥7.0% (≥53 mmol/mol) who received
Gla-100 and had no missing values for all covariates included in the analy-
sis (n = 2626; 76.9%). Initially, univariable regression analysis was per-
formed to measure associations between attaining HbA1c less than 7.0%
(<53 mmol/mol) and baseline variables, including age, sex, diabetes dura-
tion, body weight, BMI, fasting C-peptide, HbA1c, FPG and 2-h SMPG. In
addition, explanatory factors such as changes in FPG, 2-h SMPG, body
weight, final Gla-100 dose, sulfonylurea use and hypoglycaemia during
the 24-week study period were incorporated in the statistical models
using either continuous or categorical variables. The cut-offs chosen for
categorical variables such as baseline HbA1c (</≥8.5%; </≥69 mmol/
mol), baseline FPG (</≥11.1 mmol/L) or baseline 2 h-SMBG
(</≥ 11.7 mmol/L) approximately referred to the corresponding means of
the “good responder” group, whereas cut-offs for body weight
(</≥83 kg), BMI (</≥30 kg/m2) and diabetes duration (</≥10 years) were
considered clinically useful by informal author review. Covariates with a
P value of < 0.05 were then included in a stepwise logistic multivariable
regression analysis using SAS software (version 9.4; SAS Institute, Cary,
North Carolina) with an entry and retention threshold of P < 0.15. In addi-
tion, continuous predictors were standardized by subtracting the mean,
and divided by the standard deviation (SD), allowing the comparison of
odds ratios (ORs) of predictors to determine their importance within the
model (Table S2). A Hosmer and Lemeshow Goodness-of-Fit Test was
run on the logistic model to determine the significance between the
observed and predicted probabilities, to confirm that there was no lack-
of-fit problem and that the linear assumption was therefore reasonable.
The final models consisted of the following covariates: sex, diabetes dura-
tion, baseline HbA1c, baseline FPG, baseline 2-h SMPG, baseline body
weight, BMI, sulfonylurea use during the study, change in body weight
and hypoglycaemia during the study.
3 | RESULTS
3.1 | Participant characteristics and demographic
variables
A total of 7386 individuals participated in the 16 RCTs, of whom
3415 were initiated on once-daily Gla-100 and were thus eligible for
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inclusion in the analysis. Baseline clinical characteristics according to
HbA1c responder groups are presented in Table 1. At 24 weeks,
46.4% of participants achieved a good glycaemic response, as defined
by an HbA1c level less than 7.0% (<53 mmol/mol) and 53.6% of par-
ticipants had HbA1c levels ≥7.0% (53 mmol/mol). At 24 weeks, 43.6%
and 27.7% of participants who achieved an HbA1c response <7.0%
(53 mmol/mol) and ≥7.0% (53 mmol/mol), respectively, achieved an
FPG target of ≤5.6 mmol/L (≤100 mg/dL) (Table 2). Age and fasting
C-peptide were similar across the two HbA1c responder groups, with
a higher percentage of men than women in the good-responder
group.
3.2 | Insulin dose and glycaemic control
Mean Gla-100 starting doses ranged from 12.8 to 13.9 U/d (0.15 to
0.17 U/kg/d) in both responder groups (Table 1, Figure 1A). Mean
final daily Gla-100 doses at Week 24 were 38.1 U (0.42 U/kg) and
41.4 U (0.46 U/kg) in the HbA1c <7.0% and HbA1c ≥7.0% groups,
respectively (Table 2, Figure 1A and Figure S2A). The corresponding
mean Gla-100 dose increments were 25.3 (0.27) and 27.5 U/d
(0.29 U/kg/d) in the two HbA1c responder groups, respectively. The
good-responder group had a greater reduction in HbA1c from base-
line to Week 24 of 2.02% (22.1 mmol/mol) compared with the poor-
responder group, in which HbA1c decreased by 1.13% (12.4 mmol/mol)
(Table 2, Figure 1B and Figure S2A). The larger decrement in
HbA1c in the good-responder group was achieved despite start-
ing with the lowest baseline HbA1c level (8.41% vs. 9.01%) and
requiring the lowest final insulin dose (0.15 vs. 0.17 U/kg)
(Table 2, Figure 1B and Figure S2B). Interestingly, in both
responder groups, an inverse relationship was observed between
insulin dose and frequency of hypoglycaemia (Table 2). Those
participants who did not experience hypoglycaemia events had
the highest insulin doses and dose increments at 24 weeks. The
Gla-100 dose and dose increments at 24 weeks according to fre-
quency of hypoglycaemia are shown in Figure S3.
HbA1c change within each of the responder groups differed only
slightly among the different OADs used during the study period
(Table S1). However, a smaller percentage of individuals reached
HbA1c target at 24 weeks with concomitant sulfonylurea compared
with the other OAD groups (32% vs 49%-57%).
FPG and 2-h SMPG levels at baseline and at 24 weeks were
higher in the poor responder group (Figure 1C, Figure S2C and
Figure S4), although the reductions in these parameters during the
course of the study were essentially similar in both responder groups:
−4.1 to −4.2 mmol/L (−73.8 to −76.5 mg/dL) for FPG and −3.1 to
−3.1 mmol/L (−56.0 to −56.7 mg/dL) for overall 2-h SMPG (Table 2).
The 2-h SMPG levels at 24 weeks were higher in the poor-responder
group compared with the good-responder group after each meal
(breakfast, lunch and evening meal) (Figure S4).
3.3 | Hypoglycaemia
The incidence and event rate of overall hypoglycaemia (PG <70 mg/dL;
<3.9 mmol/L) or severe hypoglycaemia over 24 weeks was higher
TABLE 1 Baseline characteristics of study participants according to Week 24 HbA1c responder groups
Good responders Poor responders
HbA1c <7.0%
(<53 mmol/mol)
All
HbA1c ≥7.0%
(≥53 mmol/mol)
Sub-optimal
HbA1c 7.0%-8.0%
(53-64 mmol/mol)
Minimal
HbA1c >8.0%
(>64 mmol/mol)
n = 1584 n = 1831 n = 1262 n = 569
Age (median, range), y 57.9 (26.7-82.4) 57.8 (19.6-86.2) 58.1 (19.6-84.7) 57.1 (21.3-86.2)
Men, n (%) 901 (56.9) 916 (50.0) 641 (50.8) 275 (48.3)
Body weight, kg 87.6 (17.6) 84.8 (18.7) 85.6 (18.3) 83.1 (19.5)
BMI, kg/m2 30.8 (5.0) 30.3 (5.4) 30.5 (5.4) 29.9 (5.4)
Diabetes duration (median,
range), y
7.0 (0.0-43) 8.0 (0.4-50.0) 8.0 (0.4-45.0) 9.0 (0.6-50.0)
Gla-100 starting dose, U/d 12.8 (5.1) 13.9 (6.6) 13.3 (5.6) 15.3 (8.2)
Gla-100 starting dose, U/kg 0.15 (0.06) 0.17 (0.09) 0.16 (0.07) 0.19 (0.11)
HbA1c, % 8.41 (0.95) 9.01 (1.01) 8.82 (0.97) 9.44 (0.98)
HbA1c, mmol/mol 68.4 (10.4) 75.0 (11.0) 72.9 (10.6) 79.7 (10.7)
n = 1567 n = 1816 n = 1251 n = 565
FPG, mmol/L 10.2 (2.7) 11.1 (3.2) 10.8 (3.0) 11.8 (3.4)
FPG, mg/dL 184.1 (49.2) 199.7 (57.3) 193.9 (54.2) 213.2 (61.8)
n = 1232 n = 1421 n = 968 n = 453
2-h SMPG overalla, mmol/L 11.7 (3.1) 13.3 (3.5) 12.7 (3.3) 14.4 (3.8)
2-h SMPG overalla, mg/dL 210.5 (55.3) 238.9 (63.9) 229.6 (59.0) 258.6 (69.4)
n = 883 n = 1216 n = 817 n = 399
Fasting C-peptide, nmol/L 1.16 (0.57) 1.14 (0.64) 1.13 (0.57) 1.16 (0.77)
Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; Gla-100, glargine 100 U/mL; HbA1c, glycated haemoglobin A1c; SMPG, self-monitored
plasma glucose.
Values are given as mean (standard deviation) or as stated. Group numbers vary with missing values.
a From 7-point SMPG profiles: average 2 h post-breakfast, lunch and evening meal.
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in the good-responder group (53.7%; 6.5  0.3 events/patient year)
compared with the poor-responder group (43.0%; 5.0  0.3 events/
patient year) (Table 2, Figure 2 and Figure S5). Similarly, the
proportion of participants who experienced one to three or four or
more episodes of hypoglycaemia were fewer in the poor-responder
group. Findings for nocturnal hypoglycaemia (PG <3.9 mmol/L) were
similar to those for overall hypoglycaemia. The incidence of severe
hypoglycaemia over 24 weeks was low at 2.0% in the responder
groups.
In both responder groups, individuals who experienced the high-
est number of hypoglycaemia events had the lowest baseline fasting
C-peptide levels and the lowest final Gla-100 dose (U/kg), a difference
that was more evident in the poor-responder group (Figure 2).
3.4 | Body weight
Baseline and 24-week mean body weights were lower in the poor-
responder group compared with the good-responder group (Tables 1
and 2). Mean change in body weight was lower in the good-responder
group (+1.4 kg) than in the poor-responder group (+2.4 kg) (Table 2).
Within each responder group, participants with the lowest mean
weight at baseline and at 24 weeks experienced a higher number of
hypoglycaemia events. This was more notable in the poor-responder
group, in which those experiencing four or more events had the low-
est body weight at baseline and at 24 weeks, despite the greater
weight gain during the study period (Figure S6).
3.5 | Factors associated with attainment of HbA1c
<7.0% (<53 mmol/mol) at 24 weeks
Univariable analysis identified potential explanatory factors among
baseline demographic characteristics, as well as clinical variables,
at 24 weeks and during the study period that were related to the
attainment of an HbA1c target of <7.0% (<53 mmol/mol) (Table 3).
The relationship between baseline HbA1c values and the probabil-
ity of reaching an end-of-trial target HbA1c of <7.0% (<53 mmol/mol)
is illustrated in Figure 1D, corresponding to an OR of 0.53 (95% confi-
dence interval [CI], 0.50-0.58) per 1%-unit (10.9 mmol/mol)
TABLE 2 Outcome measures at 24 weeks and change from baseline according to Week 24 HbA1c responder groups
Good responders Poor responders
HbA1c <7.0%;
<53 mmol/mol
All
HbA1c ≥7.0%
(≥53 mmol/mol)
Sub-optimal
HbA1c 7.0%-8.0%
(53-64 mmol/mol)
Minimal
HbA1c >8.0%
(>64 mmol/mol)
Participants, n (% of total) 1584 (46.4) 1831 (53.6) 1262 (37.0) 569 (16.6)
HbA1c n = 1584 n = 1831 n = 1262 n = 569
Week 24, % 6.39 (0.41) 7.88 (0.87) 7.42 (0.30) 8.91 (0.83)
Change from baseline, % −2.02 (0.99) −1.13 (1.09) −1.40 (0.97) −0.54 (1.10)
Week 24, mmol/mol 46.4 (4.5) 62.6 (9.5) 57.6 (3.3) 73.9 (9.1)
Change from baseline, mmol/mol −22.1 (10.8) −12.4 (11.9) −15.3 (10.6) −5.9 (12.0)
FPG, mmol/L n = 1559 n = 1799 n = 1244 n = 555
Week 24 6.0 (1.5) 7.0 (2.3) 6.6 (1.9) 7.8 (3.0)
Change from baseline −4.2 (2.9) −4.1 (3.6) −4.1 (3.3) −4.0 (4.2)
≤5.6 mmol/L at Week 24, % 43.6 27.7 30.4 21.7
2-h SMPG overalla, mmol/L n = 1221 n = 1387 n = 952 n = 435
Week 24 8.6 (1.9) 10.2 (2.7) 9.6 (2.2) 11.4 (3.1)
Change from baseline −3.1 (3.1) −3.1 (3.5) −3.1 (3.4) −3.1 (3.8)
<7.8 mmol/L at Week 24, % 39.1 17.7 26.3 7.1
2-h SMPG breakfasta, mmol/L n = 1201 n = 1354 n = 927 n = 427
Week 24 8.3 (2.6) 9.7 (3.2) 9.3 (2.9) 10.7 (3.5)
Change from baseline −4.0 (4.0) −4.0 (4.3) −4.0 (4.2) −4.0 (4.6)
Gla-100 dose, U/kg n = 1584 n = 1831 n = 1262 n = 569
Week 24 0.42 (0.23) 0.46 (0.26) 0.44 (0.24) 0.51 (0.29)
Change from baseline 0.27 (0.23) 0.29 (0.26) 0.28 (0.25) 0.32 (0.30)
Hypoglycaemiab n = 1584 n = 1831 n = 1262 n = 569
Incidence, % (SE) 53.7 (1.25) 43.0 (1.16) 46.5 35.2
Events/person-year, n 6.5 (0.3) 5.0 (0.3) 5.3 (0.3) 4.4 (0.5)
Body weight, kg n = 1581 n = 1811 n = 1252 n = 559
Week 24 89.0 (17.9) 87.2 (18.9) 87.8 (18.6) 85.7 (19.6)
Change from baseline 1.4 (3.8) 2.4 (3.4) 2.3 (3.4) 2.8 (3.5)
Abbreviations: FPG, fasting plasma glucose; Gla-100, glargine 100 U/mL; HbA1c, glycated haemoglobin A1c; PG, plasma glucose; SE, standard error;
SMPG, self-monitored plasma glucose.
Values are given as mean (standard deviation) or as stated. Group numbers vary with missing values.
a From 7-point SMPG profiles: 2-h post-prandial.
b Overall hypoglycaemia: PG <70 mg/dL (<3.9 mmol/L).
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(Table 3). Female sex, known duration of diabetes, sulfonylurea use,
hypoglycaemia incidence during the study and change in body weight
were all negatively associated with the probability of achieving an
HbA1c of <7.0% (<53 mmol/mol) (Table 3). Age, baseline C-peptide
levels, change in FPG and 2-h SMPG, as defined previously, over the
24-week study period did not contribute to predicting whether an
HbA1c target of <7.0% (<53 mmol/mol) would be achieved.
Covariates remaining in the final multivariable model analysis
are represented in Table 3. Using categorical cut-offs, participants
with a baseline HbA1c of ≥8.5% (≥69 mmol/mol) were 0.35 times
less likely to achieve an HbA1c target of <7.0% (<53 mmol/mol)
than those with an HbA1c of <8.5% (<69 mmol/mol). Further pre-
dictive or explanatory factors of a good response in HbA1c within
this model included higher baseline body weight, lower baseline
2-h SMPG levels and hypoglycaemia occurring during treatment.
Moreover, a longer duration of diabetes (≥10 vs <10 years), female
sex, continued use of sulfonylurea and a greater change in weight
were associated with a lower likelihood of reaching the target
HbA1c level of <7.0%.
Using a multivariable analysis model with continuous variables,
baseline HbA1c was the strongest predictor of reaching the target
HbA1c level, with odds decreasing by a factor of 0.53 (95% CI,
0.48-0.60) per 1%-unit increase in HbA1c (OR, 0.94 [95% CI,
0.94-0.95] per 1 mmol/mol increase) (Table 3). Although significant,
the predictive power of diabetes duration and baseline 2-h SMPG was
less (Table 3). Sex and hypoglycaemia during the study were consis-
tent with the findings used with categorical cut-offs.
4 | DISCUSSION
Recognition of the characteristics that influence treatment outcomes
will enable clinicians to develop more efficient treatment strategies
and provide better advice to individuals with T2DM. This post-hoc
analysis of pooled, participant-level data concerning 3415 individuals
with T2DM indicated that 54% did not reach the HbA1c goal of
<7.0% (<53 mmol/mol) when given supplementary Gla-100 over a
period of 24 weeks. Several variables were identified with both
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univariable and multivariable analyses that appeared to be associated
with achieving target HbA1c levels of <7.0%.
Baseline HbA1c was the most powerful predictor of response
with observational, univariable and multivariable analyses, consistent
with other studies involving supplementary basal and other insulins in
individuals with T2DM.10–13 The odds of achieving HbA1c <7.0%
(<53 mmol/mol) decreased by 50% (OR 0.53 [95% CI, 0.48-0.60]) per
%-unit after adjusting for other variables. However, only 26.5% and
17.7% of individuals reached a target HbA1c of <7.0% (<53 mmol/mol)
at 24 weeks, with a baseline HbA1c of >8.0% (>64 mmol/mol)
and >8.5% (>69 mmol/mol), respectively. These percentages were fur-
ther reduced to 9%-12% and 4%-7%, with coexisting elevated 2-h
SMPG (>11.7 mmol/L) or diabetes duration ≥10 years at baseline,
respectively (data not shown). Nonetheless, a decrease in HbA1c of
1.1% (12.4 mmol/mol) was achieved in the poor-responder group,
with end-of-treatment HbA1c ≥7.0% (≥53 mmol/mol), representing
significant gains in glycaemic control despite failure to reach the tar-
get HbA1c level of <7.0% (<53 mmol/mol). The good- and sub-opti-
mal-responder groups comprise 83% of the participants; however, a
considerable proportion of individuals (17%) remained in poor control,
with an end-of-treatment HbA1c of >8.0% (>64 mmol/mol).
We also observed that an increase in body weight over 24 weeks
was modestly associated with failure to attain a good HbA1c response
and was consistent with the premise that lifestyle modification, espe-
cially in conjunction with commencing basal insulin, is important in
achieving glucose targets. Unexpectedly, higher baseline body weight
or a higher BMI were modest and independent predictors of achieving
a better response.6,10 In addition, the poor-responder group received
more insulin as a consequence of greater dose titration, but had fewer
hypoglycaemia events, suggesting the possibility of more insulin
resistance.
Although the final insulin dose when weight adjusted was clearly
different between the HbA1c responder groups, this could be related,
in part, to the differences in body weight rather than dose. The final
insulin dose was not retained as an explanatory variable in the multi-
variable analyses, suggesting that it was closely associated with
another strong predictor that could only be baseline HbA1c.
Hypoglycaemia was a modestly powerful explanatory factor,
with a higher incidence associated with attainment of target levels in
accordance with other reports,14–16 with the exception of the
ACCORD study.17 In our study population, hypoglycaemia occur-
rence was not a barrier to better control, even though, in short-term,
treat-to-target studies, the overall incidence is high. Within each
responder group, a higher event rate was associated with lower insu-
lin dose and lower baseline C-peptide levels, as reported by others,
suggesting the existence of sub-populations with greater insulin
deficiency and higher insulin sensitivity.2,18,19 Overall, the contribu-
tion of diabetes duration to predicting the achievement of glycaemic
outcome is lower than that of HbA1c. This could be a consequence
of the burden of disease, as those using two OADs during the study
achieved less benefit overall, consistent with previous
observations.6,10–12 In addition, those using sulfonylureas during the
study were less successful in achieving the HbA1c target, indepen-
dently of other factors, such as hypoglycaemia and weight gain, with
the odds changing only marginally between univariable and multivar-
iable analyses (OR of 0.61 [95% CI, 0.52-0.71] vs OR of 0.59 [95%
CI, 0.49-0.71], respectively).
HbA1c is associated with FPG and PPG; thus, the finding on uni-
variable analysis that these measures predict achievement of a better
response at 24 weeks was expected. Nonetheless, the odds per FPG
at an OR of 0.91 (95% CI, 0.89-0.93) are modest and less than an OR
of 0.86 (95% CI, 0.84-0.89) per 1 mmol/L for 2-h SMPG. Knowledge
of FPG does not supplement the ability to predict improvement in gly-
caemic control if the HbA1c level is known. In the prospective
A1chieve study involving a variety of insulin types, lower FPG and
PPG values predicted greater change in HbA1c.10
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TABLE 3 Univariable and multivariable analyses using potential prognostic and explanatory factors to estimate the probability of reaching HbA1c
less than 7.0% (<53 mmol/mol) at Week 24 in participants with type 2 diabetes
Variable Categorical or continuous Odds ratio (95% CI) P value
Univariable analysis
Age at baseline Per 10 y 1.02 (0.95, 1.10) 0.513
Sex Women vs men 0.76 (0.66, 0.87) <0.0001
Body weight at baseline ≥83.0 vs <83.0 kg 1.38 (1.20, 1.58) <0.0001
Continuous (per 10 kg)a 1.09 (1.05, 1.13) <0.0001
BMI at baseline ≥30.0 vs <30.0 kg/m2 1.21 (1.06, 1.38) 0.006
Continuous (per 5 kg/m2) 1.09 (1.02, 1.16) 0.008
Diabetes duration ≥10 vs <10 y 0.61 (0.53, 0.70) <0.0001
Continuous (per year)a 0.96 (0.95, 0.97) <0.0001
HbA1c at baseline ≥8.5 vs <8.5%b 0.35 (0.30, 0.40) <0.0001
Continuous (per 1 mmol/mol)a 0.94 (0.94, 0.95) <0.0001
Continuous (per 1%-unit)a 0.53 (0.50, 0.58) <0.0001
FPG at baseline ≥11.1 vs <11.1 mmol/Lc 0.59 (0.51, 0.68) <0.0001
Continuous (per 1 mmol/L)a 0.91 (0.89, 0.93) <0.0001
Continuous (per 10 mg/dL)a 1.00 (0.99, 1.00) <0.0001
2-h SMPG at baseline (all meals) ≥11.7 vs <11.7 mmol/Ld 0.48 (0.41, 0.56) <0.0001
Continuous (per 1 mmol/L)a 0.86 (0.84, 0.89) <0.0001
Continuous (per 10 mg/dL)a 0.99 (0.99, 0.99) <0.0001
Baseline fasting C-peptide ≥1.2 vs <1.2 nmol/L 1.00 (0.84, 1.20) 0.97
Continuous (per 0.2 nmol/L)a 1.00 (1.00, 1.00) 0.28
Sulfonylurea use during study Yes vs no 0.61 (0.52, 0.71) <0.0001
Hypoglycaemiaa during study No vs yes 0.65 (0.57, 0.75) <0.0001
Change in FPG Continuous (per 10 mg/dL) 0.99 (0.98, 1.00) 0.19
0.19Continuous (per 1 mmol/L)a 0.99 (0.97, 1.01)
Change in 2-h SMPG (all meals) Continuous (per 10 mg/dL) 1.00 (0.99, 1.01) 0.76
0.76Continuous (per 1 mmol/L)a 1.00 (0.97, 1.02)
Change in body weight Continuous (per 1.0 kg) 0.92 (0.90, 0.94) <0.0001
Final Gla-100 dose Continuous (per 0.1 U/kg) 0.93 (0.91, 0.96) <0.0001
Multivariable analysis model using categorical and continuous variables
Sex Women vs men 0.76 (0.64, 0.91) 0.0021
Diabetes duration ≥10 vs <10 y 0.63 (0.53, 0.75) <0.0001
HbA1c at baseline ≥8.5 vs <8.5%b 0.38 (0.32, 0.45) <0.0001
2-h SMPG at baseline (all meals) ≥11.7 vs <11.7 mmol/Ld 0.73 (0.61, 0.87) 0.0005
Body weight at baseline ≥83.0 vs <83.0 kg 1.29 (1.09, 1.54) 0.0034
Sulfonylurea use during study Yes vs no 0.59 (0.49, 0.71) <0.0001
Change in body weight Continuous (per 1.0 kg) 0.94 (0.91, 0.96) <0.0001
Hypoglycaemiaa during study No vs yes 0.62 (0.53, 0.74) <0.0001
Multivariable analysis model using continuous variables
Sex Women vs men 0.70 (0.60, 0.83) <0.0001
Diabetes duration Per year 0.96 (0.95, 0.98) <0.0001
HbA1c at baseline Per 1 mmol/mol 0.94 (0.94, 0.95) <0.0001
Per 1%-unit 0.53 (0.48, 0.60) <0.0001
FPG at baseline Per 1 mmol/L 1.06 (1.02, 1.11) 0.003
Per 1 mg/dL 1.00 (1.00, 1.01) 0.0023
2-h SMPG at baseline (all meals) Per 1 mmol/L 0.93 (0.90, 0.96) <0.0001
Per 1 mg/dL 1.00 (0.99, 1.00) 0.0005
BMI at baseline Per 5.0 kg/m2 1.19 (1.08, 1.31) 0.0003
Change in body weight Per 1.0 kg 0.94 (0.92, 0.97) <0.0001
Hypoglycaemiaa during study No vs yes 0.64 (0.54, 0.76) <0.0001
Abbreviations: BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose; Gla-100, glargine 100 U/mL; HbA1c, glycated haemoglobin
A1c; PG, plasma glucose; SMPG, self-monitored plasma glucose.
For multivariable analysis, n = 2626 patients were included. Outcomes of univariable and multivariable analysis using standardized predictors are shown in
Table S2.
a Confirmed with PG <3.9 mmol/L or severe hypoglycaemia.
b ≥69 vs <69 mmol/mol.
c ≥200 vs <200 mg/dL.
d ≥210 vs <210 mg/dL.
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In the present study, individuals with higher HbA1c levels at
24 weeks recorded higher 2-h SMPG values, both at baseline and at
endpoint, for each meal. The absolute reduction in PPG between
baseline and 24 weeks appears to be greatest with breakfast and least
with dinner, possibly reflecting the waning biological activity of Gla-
100 toward the end of the 24-hour period. Interestingly, change in
FPG and, to a lesser extent, the 2-h SMPG was only slightly greater in
the good- than in the sub-optimal- or minimal-responder groups;
although this was proportionately less in the latter group because
baseline levels were much higher.
Female sex was a modest predictor of difficulty in attaining the
HbA1c target on basal insulin, an association that survived into the
multivariable models and is consistent with previous reports.6,9,10,20
A limitation of this study is the focus on HbA1c goal attainment
rather than using HbA1c as a continuous variable that might have
identified additional factors important for improving glucose control
rather than goal achievement.
While findings of the present analysis are consistent with those
of other RCTs, pharmaco-epidemiological and prospective cohort
studies involving basal insulin and other insulin types,6,8,10–12,20,21 the
analysis reflects only a subpopulation of those starting insulin in the
real world.6
This study focused on whether patients with poorly controlled
T2DM while using an OAD can achieve the recommended HbA1c
goal of <7.0% with the introduction of basal insulin Gla-100. This
pooled analysis of individuals with T2DM with a mean HbA1c of 8.7%
(72 mmol/mol) at baseline demonstrated that 54% of the study popu-
lation did not achieve an HbA1c level of <7.0% (<53 mmol/mol) fol-
lowing the addition of basal insulin.
The results further suggest that, in individuals with a higher base-
line HbA1c (>8.0%; >64 mmol/mol), basal insulin supplementation
may need to be more aggressive, while also considering the risk of
hypoglycaemia. Therefore, when an adequate response is not
achieved, consideration should be given to other therapies to address
excessive PPG excursions, such as prandial insulin, sodium glucose co-
transporter 2 inhibitors or a GLP-1 RA in a free or fixed combination
with insulin. Early introduction of basal insulin in combination with a
GLP-1 RA may be an option for individuals with T2DM with persis-
tently poor glycaemic control despite the use of multiple OADs.22
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